Clinical Trial Detail

NCT ID NCT01804101
Title Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fred Hutchinson Cancer Research Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

CPX-351

Age Groups: senior adult

No variant requirements are available.